French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: no specific intervention.
- Who it may be relevant to
- Registry conditions: Immune Thrombocytopenia, Autoimmune Hemolytic Anemia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
CARMEN is a national, real-world clinical registry of all adult patients with incident diagnosis of Immune thrombocytopenia (ITP) or Autoimmune Hemolytic anemia (AIHA) patients in France. It is aimed at describing ITP and AIHA clinical features, assessing the real-world risk-benefit ratio of treatments and adherence to guidelines for ITP and AIHA management.
Interventions
- Other no specific intervention
Primary outcome measures
- Incidence of Immune thrombocytopenia (ITP) and AIHA [Time frame: Baseline]
- Natural evolution and events [Time frame: Baseline and follow-up]
Secondary outcome measures (8)
- Response [Time frame: 15 years]
- Complete rate [Time frame: 15 years]
- Treatment lines [Time frame: 15 years]
- Adverse drug reactions [Time frame: 15 years]
- Bleeding [Time frame: 15 years]
- Rescue treatment [Time frame: 15 years]
- Adherence to ITP management guidelines. [Time frame: 15 years]
- Events [Time frame: 15 years]
Eligibility criteria
Inclusion criteria
- adult patients (18+ year-old)
- newly diagnosed for ITP/AIHA or initiation of FOSFAMATINIB
Exclusion criteria
\- opposition to data collection
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Service de Médecine Interne — Toulouse
Publications
- Larue M, Moulis G, Rueter M, Audia S, Comont T, Terriou L, Viallard JF, Pan-Petesch B, Royer B, Bonnotte B, Galicier L, Lambotte O, Lefrere F, Cheze S, Ebbo M, Duong TA, Boutin E, Languille L, Mahevas M, Godeau B, Canoui-Poitrine F, Michel M. Efficacy and safety of dapsone in adult primary immune thrombocytopenia. Blood Adv. 2025 Apr 22;9(8):1976-1983. doi: 10.1182/bloodadvances.2024014939. PMID 39874521
Identifiers
NCT: NCT02877706 · RC31/12/0386